Literature DB >> 8866741

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment.

H Y Meltzer1, P A Thompson, M A Lee, R Ranjan.   

Abstract

Cognitive impairment is present in the majority of schizophrenic patients, even at the onset of psychosis. It is a relatively stable characteristic in most patients, usually with little progression over the course of illness, but sometimes progresses to severe dementia. The results of studies of the effects of typical neuroleptic drugs on cognitive functioning in schizophrenia are conflicting. Clozapine, which has superior antipsychotic effects compared to typical neuroleptic drugs, has been reported to improve executive function, verbal fluency, attention, and recall memory in two of three studies. Cognitive measures predict work function and overall outcome on clozapine as assessed by the Global Assessment Scale and Quality-of-Life Scale in neuroleptic--resistant schizophrenia. Improvement in cognitive function by clozapine may be a major reason for expanding its currently limited utilization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866741     DOI: 10.1016/0893-133X(95)00202-O

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  16 in total

Review 1.  Functional impairment and cognition in bipolar disorder.

Authors:  C A Zarate; M Tohen; M Land; S Cavanagh
Journal:  Psychiatr Q       Date:  2000

2.  Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia.

Authors:  Clare Reeder; Nicola Smedley; Kate Butt; Diana Bogner; Til Wykes
Journal:  Schizophr Bull       Date:  2006-08-10       Impact factor: 9.306

3.  A naturalistic study of grey matter volume increase after early treatment in anti-psychotic naïve, newly diagnosed schizophrenia.

Authors:  Michelle Y Deng; Gráinne M McAlonan; Charlton Cheung; Cindy P Y Chiu; Chi W Law; Vinci Cheung; Pak C Sham; Eric Y H Chen; Siew E Chua
Journal:  Psychopharmacology (Berl)       Date:  2009-07-30       Impact factor: 4.530

4.  5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.

Authors:  Vladimir M Pogorelov; Ramona M Rodriguiz; Jianjun Cheng; Mei Huang; Claire M Schmerberg; Herbert Y Meltzer; Bryan L Roth; Alan P Kozikowski; William C Wetsel
Journal:  Neuropsychopharmacology       Date:  2017-03-15       Impact factor: 7.853

Review 5.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 6.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

Review 7.  Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.

Authors:  Sandra L Tunis; Haya Ascher-Svanum; Michael Stensland; Bruce J Kinon
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 8.  Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.

Authors:  Stacy A Castner; Patricia S Goldman-Rakic; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

9.  Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.

Authors:  Tomiki Sumiyoshi; A Roy; C-H Kim; K Jayathilake; M A Lee; C Sumiyoshi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

Review 10.  Complex relationships of nicotinic receptor actions and cognitive functions.

Authors:  Edward D Levin
Journal:  Biochem Pharmacol       Date:  2013-08-06       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.